Indaptus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Net Income	-15.42	-14.32	-7.71	-3.58	-47.6	Upgrade
Depreciation & Amortization	0	0	0	0	0.85	Upgrade
Share-Based Compensation	2.97	2.96	1.51	0.14	3.22	Upgrade
Other Operating Activities	-0.95	-1.71	-5.09	0.12	14.48	Upgrade
Operating Cash Flow	-13.41	-13.08	-11.29	-3.32	-29.05	Upgrade
Capital Expenditures	0	0.17	0.45	0	-0.92	Upgrade
Change in Investments	17.14	-16.6	0	0	0.58	Upgrade
Other Investing Activities	-	-	-	-	-2.87	Upgrade
Investing Cash Flow	17.14	-16.43	0.45	0	-3.21	Upgrade
Share Issuance / Repurchase	0	0	30.34	0	2.37	Upgrade
Debt Issued / Paid	0	0	5	1.16	0	Upgrade
Other Financing Activities	-	-	13	-	-	Upgrade
Financing Cash Flow	0	0	48.34	1.16	2.37	Upgrade
Exchange Rate Effect	0	0	0	0	-0.07	Upgrade
Net Cash Flow	3.74	-29.51	37.49	-2.16	-29.89	Upgrade
Free Cash Flow	-13.41	-12.91	-10.84	-3.32	-29.97	Upgrade
Free Cash Flow Per Share	-1.60	-1.56	-2.65	-1.71	-70.97	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).